$21.94
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?
Overview
52-week range
$4.07
$24
90% of range
Avg surprise (last 3)
+16.8%
Avg reaction (last 2)
-1.9%
50% positive
Latest IV / EM
197%
EM ±45.1% · $23 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 8, 2026 | Mar/2026 | $-0.52 | $-0.71 | +26.8% | -44.4% | +1.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.56 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.60 | $-0.56 | -7.1% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.36 | $-0.52 | +30.8% | — | -4.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-6.70 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-7.94 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-7.76 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-8.74 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$0.65 | -$0.60 | -8.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | — | $2M | $2M | $1M | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-25M | — | $-23M | $-25M | $-16M | — | $-25M | $-15M |
| Net income | $-22M | — | $-20M | $-22M | $-13M | — | $-23M | $-14M |
| EPS (diluted) | $-0.52 | — | $-0.56 | $-0.60 | $-0.36 | — | $-6.70 | $-7.94 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $242M | $189M | $216M | $220M | $257M | $354M | $334M | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $392M | $287M | $291M | $302M | $325M | $357M | $336M | — |
| Total assets | $398M | $295M | $305M | $322M | $344M | $358M | $337M | — |
| Long-term debt | — | — | $0 | $0 | $1M | $3M | $4M | — |
| Total liabilities | $19M | $23M | $28M | $27M | $31M | $35M | $24M | — |
| Total equity | $379M | $272M | $277M | $295M | $313M | $323M | $314M | $-197M |